Market Place
Sourcing Support
Oncopeptides Expands WODA Partnership To Africa And Eurasia
04 Sep 2024 //
GLOBENEWSWIRE
Oncopeptides, Vector partner to distribute Oncopeptides’ Pepaxti in MENA
30 Mar 2024 //
PHARMABIZ
FDA formally pulls Oncopeptides` cancer drug after prolonged back-and-forth
23 Feb 2024 //
ENDPTS
CDER challenges Oncopeptides’ appeal over Pepaxto withdrawal
13 Sep 2023 //
ENDPTS
FDA publishes Oncopeptides’ withdrawal appeal for Swedish biotech’s Pepaxto
25 Aug 2023 //
ENDPTS
Oncopeptides challenges FDA`s withdrawal of cancer drug`s accelerated approval
11 Aug 2023 //
ENDPTS
Oncopeptides says Swedish authorities ended probe into CSO Jakob Lindberg
30 May 2023 //
ENDPTS
Oncopeptides exec is arrested for allegedly passing insider information
08 Mar 2023 //
ENDPTS
Oncopeptides Chief Financial Officer Holger Lembrer takes office today
18 Jan 2023 //
PR NEWSWIRE
The C-suite shuffle: Oncopeptides, Zymeworks replace execs to start 2023
05 Jan 2023 //
ENDPTS
Oncopeptides provides update on Pepaxto US marketing authorization
07 Dec 2022 //
PRNEWSWIRE
FDA pulls Oncopeptides` Pepaxto indication
07 Dec 2022 //
ENDPTS
Oncopeptides enters into a loan facility agreement with EU Investment Bank
25 Nov 2022 //
PRNEWSWIRE
Oncopeptides` Pepaxti has been granted marketing authorization in the UK
11 Nov 2022 //
PRNEWSWIRE
Oncopeptides announces the market potential for Pepaxti in Europe
09 Nov 2022 //
PRNEWSWIRE
Oncopeptides publishes Q3 report 2022
09 Nov 2022 //
PRNEWSWIRE
Oncopeptides says trial data good, but not enough to sway FDA
28 Oct 2022 //
FIERCEPHARMA
Oncopeptides PIII LIGHTHOUSE study confirms clinical benefit of melflufen
26 Oct 2022 //
PRNEWSWIRE
Pepaxto Saw Public Airing Of Unusual Discord Between US FDA, Oncopeptides
05 Oct 2022 //
PINK SHEET
Oncopeptides starts commercialization of Pepaxti in Europe
03 Oct 2022 //
PRNEWSWIRE
FDA adcomm rejects Oncopeptides` multiple myeloma drug Pepaxto
24 Sep 2022 //
FIERCEPHARMA
Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)
23 Sep 2022 //
PRNEWSWIRE
ODAC gives a big thumbs-down to Oncopeptides` dangling approval in myeloma
22 Sep 2022 //
ENDPTS
Oncopeptides`s Pepaxti (melphalan flufenamide) Receives Approval in Europe
06 Sep 2022 //
EMA
EC approves Oncopeptides` Pepaxti for r/r multiple myeloma
18 Aug 2022 //
PRNEWSWIRE
Number of shares and votes in Oncopeptides
29 Jul 2022 //
PRNEWSWIRE
FDA puts the microscope on 2 more cancer approvals without voluntary withdrawals
23 Jul 2022 //
FIERCEPHARMA
FDA announces an ODAC meeting to discuss benefit/risk profile of Pepaxto
20 Jul 2022 //
PRNEWSWIRE
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
28 Jun 2022 //
PRNEWSWIRE
Europe’s CHMP signs off on Oncopeptides` multiple myeloma drug
24 Jun 2022 //
FIERCEPHARMA
Annual General Meeting in Oncopeptides AB (publ)
25 May 2022 //
PRNEWSWIRE
Oncopeptides publishes Q1 report 2022
04 May 2022 //
PRNEWSWIRE
Invitation to presentation of Q1 report
27 Apr 2022 //
PRNEWSWIRE
Oncopeptides publishes the 2021 Annual Report
21 Apr 2022 //
PRNEWSWIRE
Number of shares and votes in Oncopeptides
30 Mar 2022 //
PRNEWSWIRE
3 months after pulling Pepaxto, Oncopeptides reverses stance
25 Jan 2022 //
FIERCEPHARMA
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
12 Jan 2022 //
PRNEWSWIRE
Oncopeptides presents new melflufen data at ASH
10 Dec 2021 //
PRNEWSWIRE
Jakob Lindberg appointed CEO of Oncopeptides
15 Nov 2021 //
PRNEWSWIRE
LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
15 Nov 2021 //
PHARMABIZ
Oncopeptides has announced the Nomination Committee
12 Nov 2021 //
PRNEWSWIRE
Oncopeptides appoints Annika Muskantor as interim CFO
01 Nov 2021 //
PRNEWSWIRE
Oncopeptides` shares plunge as it pulls Pepaxto from the market
23 Oct 2021 //
FIERCEPHARMA
Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
22 Oct 2021 //
PRNEWSWIRE
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting
13 Sep 2021 //
PRNEWSWIRE
Regulatory update from US Food and Drug Administration
02 Sep 2021 //
PRNEWSWIRE
Oncopeptides presents new data from OCEAN and PORT study - abstracts online
26 Aug 2021 //
BIO SPACE
Oncopeptides publishes report for Q2 2021
19 Aug 2021 //
PRNEWSWIRE
Invitation to presentation of the Q2 2021 results
12 Aug 2021 //
PRNEWSWIRE
FDA warns of myeloma drug Pepaxto`s death risk
30 Jul 2021 //
FIERCEPHARMA
In halting confirmatory trial for Oncopeptides` accelerated approval
29 Jul 2021 //
ENDPTS
Regulatory update from US Food and Drug Administration
28 Jul 2021 //
PRNEWSWIRE
Oncopeptides` PEPAXTO Receives a Specific C-Code and Pass-Through Payment Status
13 Jul 2021 //
PRNEWSWIRE
Oncopeptides shares updated results from the phase 3 OCEAN study
08 Jul 2021 //
PR NEWSWIRE
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint
08 Jul 2021 //
PR NEWSWIRE
Oncopeptides says a second look at its data offers a win in cancer trial
07 Jul 2021 //
ENDPTS
Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least
25 May 2021 //
PRNEWSWIRE
Oncopeptides announces 3 abstracts accepted by the 2021 ASCO
20 May 2021 //
BIOSPACE
Oncopeptides presents clinical abstracts on melflufen at the 2021
18 May 2021 //
PRNEWSWIRE
Oncopeptides presents new clinical & preclinical melflufen data at EHA meeting
12 May 2021 //
PRNEWSWIRE
